Close Menu

NEW YORK — Fios Genomics will provide bioinformatics, statistics, and computational biology services to Charles River Laboratories International under a partnership announced Thursday. 

Edinburgh, UK-based Fios Genomics will help Charles River, of Wilmington, Massachusetts, with sourcing and analysis of multi-variant datasets to inform drug discovery. These datasets will cover microarrays, next-generation sequencing, proteomics, metabolomics, and epigenetics, plus the associated metadata, the companies said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.